ArticleProceedings of the National Academy of Sciences of the United States of America2022
Quantifying the effectiveness of betaherpesvirus-vectored transmissible vaccines.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Evaluating vectors for the design of a spillover-disrupting Lassa virus transmissible vaccine.PLoS computational biology · 2026Article
- Molecular cloning and host range analysis of three cytomegaloviruses fromJournal of virology · 2025Article
- Design of field trials for the evaluation of transmissible vaccines in animal populations.PLoS computational biology · 2025Article
- Fine-tuning the evolutionary stability of recombinant herpesviral transmissible vaccines.Proceedings. Biological sciences · 2024Article
- Review
- Optimizing the delivery of self-disseminating vaccines in fluctuating wildlife populations.PLoS neglected tropical diseases · 2023Article
- Inferring the disruption of rabies circulation in vampire bat populations using a betaherpesvirus-vectored transmissible vaccine.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- One step closer to a transmissible vaccine for rabies virus.PLoS biology · 2022Article
- Recombinant transmissible vaccines will be intrinsically contained despite the ability to superinfect.Expert review of vaccinesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Transmissible vaccines have the potential to revolutionize how zoonotic pathogens are controlled within wildlife reservoirs. A key challenge that must be overcome is identifying viral vectors that can rapidly spread immunity through a reservoir population. Because they are broadly distributed taxonomically, species specific, and stable to genetic manipulation, betaherpesviruses are leading candidates for use as transmissible vaccine vectors. Here we evaluate the likely effectiveness of betaherpesvirus-vectored transmissible vaccines by developing and parameterizing a mathematical model using data from captive and free-living mouse populations infected with murine cytomegalovirus (MCMV). Simulations of our parameterized model demonstrate rapid and effective control for a range of pathogens, with pathogen elimination frequently occurring within a year of vaccine introduction. Our results also suggest, however, that the effectiveness of transmissible vaccines may vary across reservoir populations and with respect to the specific vector strain used to construct the vaccine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.